ArticleTranslational cancer research2021
Expression patterns and clinical significances of PBK in lung cancer: an analysis based on Oncomine database.
Article in Translational cancer research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 6 citations in OpenAlex.
- Evidence for PDZ-Binding Kinase in Lung Disease With an Emphasis on PAH.Pulmonary circulation · 2026Review
- RACGAP1 promotes the progression and poor prognosis of lung adenocarcinoma through its effects on the cell cycle and tumor stemness.BMC cancer · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBased on both biological and clinical perspectives, lung cancer is a diverse disease with varied histological subtypes. At present, molecular-targeted drugs have broad application prospects in lung cancer clinical therapy. Here, we explored the expression profile of PDZ-binding kinase (PBK) in lung cancer along with its prognostic potential.
methodsWe employed the Oncomine web resource to explore the differential expression of PBK in LC tissues. Additionally, the prognostic capacity of PBK in lung cancer was explored via the Kaplan-Meier Plotter web resource.
resultsOverall, 80 studies documented remarkable differences in the expression of PBK in tumor tissue and healthy control tissue. In all studies, 63 studies showed that PBK was upregulated and 17 studies demonstrated that PBK was downregulated. Of the 80 studies, 63 studies showed an increase in PBK expression in diverse kinds of tumor tissues including the following: bladder cancer, gastric cancer, brain and CNS cancer, cervical cancer, esophageal cancer, head and neck cancer, liver cancer, breast cancer, lung cancer, colorectal cancer, lymphoma, ovarian cancer, pancreatic cancer, prostate cancer, sarcoma and others. In addition, PBK expression was increased in 774 lung cancer tissues (P<0.05). Kaplan-Meier Plotter web resource analysis, revealed that PBK levels were negatively linked to the total survival period of individuals with lung cancer (P<0.05). Subgroup evaluations demonstrated that the prognostic significance of PBK was more obvious in individuals with lung adenocarcinoma. In lung cancer categorized by gender, level I-III differentiation, and stage 1 and stage 3 of clinical staging, the survival advantage of the PBK high-expression group was remarkably lower than that of the low-expression group lung cancer patients (P<0.05).
conclusionsPBK is an oncogene that is markedly upregulated in lung cancer tissues, and it is correlated with poor prognosis. PBK can be employed as a target in the design of new drugs for lung cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.